Myriam Fernández-Sendin

发表

Novel strategies exploiting interleukin-12 in cancer immunotherapy.

I. Melero, P. Berraondo, E. Castañón, 2022, Pharmacology & therapeutics.

Scavenger Receptor class B type I is Required for 25-Hydroxycholecalciferol Cellular Uptake and Signaling in Myeloid Cells.

I. Melero, P. Berraondo, Maite Alvarez, 2020, Molecular nutrition & food research.

Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications

I. Melero, P. Berraondo, Á. Teijeira, 2021, Cancers.

Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity

F. Corrales, P. Berraondo, S. Ciordia, 2021, Frontiers in Immunology.

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

I. Melero, A. Muntasell, M. López-Botet, 2019, Oncoimmunology.

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

I. Melero, P. Berraondo, H. Hochrein, 2022, Oncoimmunology.

Production and use of adeno-associated virus vectors as tools for cancer immunotherapy.

P. Berraondo, Fernando Aranda, Myriam Fernández-Sendin, 2020, Methods in enzymology.

Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models

I. Melero, P. Berraondo, Á. Teijeira, 2022, Oncoimmunology.

Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α

P. Berraondo, J. Lasarte, N. Casares, 2019, The Journal of Immunology.

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors

I. Melero, P. Berraondo, Fernando Aranda, 2021, Journal for ImmunoTherapy of Cancer.

Advances in mRNA-based drug discovery in cancer immunotherapy

I. Melero, P. Berraondo, Irene Olivera, 2021, Expert opinion on drug discovery.

Intratumoral gene transfer of mRNAs encoding interleukin-12 in combination with decoy-resistant interleukin-18 improves local and systemic antitumor immunity.

I. Melero, P. Berraondo, C. D. de Andrea, 2022, Cancer immunology research.

Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

I. Melero, M. Rodriguez-Ruiz, W. Shen, 2021, Journal for ImmunoTherapy of Cancer.

Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.

I. Melero, E. Ames, M. Ochoa, 2022, International review of cell and molecular biology.

Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice

N. Tennagels, P. Berraondo, J. Escalada, 2021, Frontiers in Pharmacology.

Overcoming the limitations of cytokines to improve cancer therapy.

I. Melero, P. Berraondo, Fernando Aranda, 2022, International review of cell and molecular biology.

Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure

I. Melero, P. Berraondo, A. van Elsas, 2023, Molecular therapy. Nucleic acids.

Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

P. Berraondo, H. Lauterbach, Claudia Augusta Di Trani, 2024, Journal for ImmunoTherapy of Cancer.